Araştırma Makalesi
PDF Zotero Mendeley EndNote BibTex Kaynak Göster

Comparisons of treatment protocols for SARS-COV-2 in early pandemic: Single center experience ın Turkey

Yıl 2022, Cilt 12, Sayı 2, 182 - 188, 15.03.2022
https://doi.org/10.16899/jcm.1009652

Öz

Objective: In this retrospective observational study, we aimed to investigate the COVID 19 treatment protocols applied in our hospital in terms of side effects and 28-day mortality. Methods: All 621 patients diagnosed as COVID-19 and treated with any drugs were included in the study. Inclusion criteria for patients were hospitalization with COVID-19 diagnosis and being over 18 years old. The patients were divided into 4 groups according to the treatments against COVID-19: Group 1 (only favipiravir), Group 2 (hydroxychloroquine (HQ)+ Azithromycin (AZ), Group 3 (only HQ), and Group 4 (HCQ+AZ +antibiotics). The gender, age, medications, underlying comorbidities, possible side effects due to the treatments (cardiotoxicity, hepatotoxicity, nephrotoxicity), and mortality rates were evaluated. Results: There was no difference in terms of side effects between treatment groups. Mortality rates were lowest in the HQ+AZ group. HCQ+AZ treatment was the most effective treatment protocol. Conclusion: It can be concluded from the study that the higher mortality rate due to favipiravir may be due to the administration of this drug only to critically ill patients during the initial period of the pandemic.

Kaynakça

  • 1. https://www.cdc.gov/coronavirus/2019-ncov/index.html [Accessed date: 01.March. 2021].
  • 2. Turkish Republic Ministry of Health Covid-19 Guideline (https://covid19bilgi.saglik.gov.tr/depo/rehberler/COVID-19_Rehberi.pdf) [Accessed date: 01.March. 2021].
  • 3. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/[Accessed date: 01.March. 2021].
  • 4. Sun J, Deng X, Chen X, et al. Incidence of Adverse Drug Reactions in COVID-19 Patients in China: An Active Monitoring Study by Hospital Pharmacovigilance System. Clin Pharmacol Ther. 2020;108(4):791-7.
  • 5. Md Insiat Islam Rabby. Current Drugs with Potential for Treatment of Covid-19: A Literature Review. J Pharm Pharm Sci. 2020;23(1):58–64. 6. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054-62. 7. Şener A. COVİD-19 (SARS COV-2) Tedavisi. J Biotechinol & Strategic Health Res. 2020; 4: 97-104.
  • 8. Arapović J, Skočibušić S. The first two months of the COVID-19 pandemic in Bosnia and Herzegovina: Single-center experience. Bosn J Basic Med Sci. 2020;20(3):396-400.
  • 9. Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449-63. 10. Joshi S, Parkar J, Ansari Aet al. Role of favipiravir in the treatment of COVID-19. Int J Infect Dis. 2021;102:501-8.
  • 11. Ghasemnejad-Berenji M, Pashapour S. Favipiravir and COVID-19: A Simplified Summary. Drug Res (Stuttg). 2021;71(3):166-70.
  • 12. Sreekanth Reddy O, Lai WF. Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options. Chembiochem. 2021;22(6):939-48.
  • 13. Simonis A, Theobald SJ, Fätkenheuer G et al. A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2. EMBO Mol Med. 2021;13(1):e13105.
  • 14. İzci-Çetinkaya F, Karagöz H, Yıldız O. Comparison of liver safety of favipiravir and hydroxychloroquine in COVID-19 treatment. Klimik Derg 2020; 33(3): 235-40.
  • 15. Doğan E, Alkan-Çeviker S, Vurucu S, et al. [Investigation of the frequency of adverse effects in patients treated with favipiravir as SARS-CoV-2 treatment]. Klimik Derg. 2021; 34(2): 95-8.
  • 16. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-71.
  • 17. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16.
  • 18. Mutlu O, Uygun İ, Erden F. Koronavirüs Hastalığı (COVID-19) Tedavisinde Kullanılan İlaçlar. KOU Sag Bil Derg. 2020; 6(3): 167-73.
  • 19. Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A randomized clinical trial. JAMA Netw Open. 2020; 3(4): e208857
  • 20. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949. DOI: 10.1016/j.ijantimicag.2020.105949.
  • 21. Seyhan AU, Doganay F, Yilmaz E, et al. Investigation of QT Prolongation with Hydroxychloroquine and Azithromycin for the Treatment of COVID-19. J Coll Physicians Surg Pak. 2020;30(10):153-7.
  • 22. Gedikli MA, Tuzun B, Aktas, A et al. Are clarithromycin, azithromycin and their analogues effective in the treatment of COVID19? Bratisl Lek Listy. 2021;122(2):101-10.
  • 23. Réa-Neto Á, Bernardelli RS, Câmara BMD, et al. An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients. Sci Rep. 2021;11(1):9023. DOI: 10.1038/s41598-021-88509-9.
  • 24. Wang M, Liao Z. SARS-CoV-2 and COVID-19: How much do we know? Acta Virol. 2020;64(3):288-96.

Erken pandemide SARS-COV-2 tedavi protokollerinin karşılaştırılması: Türkiye'de tek merkez deneyimi

Yıl 2022, Cilt 12, Sayı 2, 182 - 188, 15.03.2022
https://doi.org/10.16899/jcm.1009652

Öz

Amaç: Bu retrospektif gözlemsel çalışmada hastanemizde uygulanan COVID 19 tedavi protokollerini, yan etkileri ve 28 günlük mortaliteyi araştırmayı amaçladık. Yöntemler: Çalışmaya COVID-19 tanısı konan ve herhangi bir ilaçla tedavi edilen 621 hastanın tamamı dahil edildi. Hastalar için dahil edilme kriterleri COVID-19 tanısı ile hastaneye yatış ve 18 yaşından büyük olmaktı. Hastalar COVID-19 tedavisine göre 4 gruba ayrıldı: Grup 1 (sadece favipiravir), Grup 2 (hidroksiklorokin (HQ)+ Azitromisin (AZ), Grup 3 (sadece HQ) ve Grup 4 (HCQ+AZ) +antibiyotikler) Cinsiyet, yaş, ilaçlar, altta yatan komorbiditeler, tedavilere bağlı olası yan etkiler (kardiyotoksisite, hepatotoksisite, nefrotoksisite) ve mortalite oranları değerlendirildi. Bulgular: Tedavi grupları arasında yan etkiler açısından fark yoktu. Mortalite oranları HQ+AZ grubunda en düşüktü. HCQ+AZ tedavisi en etkili tedavi protokolüydü. Sonuç: Çalışmada, favipiravire bağlı daha yüksek ölüm oranının, pandeminin ilk döneminde bu ilacın sadece kritik hastalara uygulanmasına bağlı olabileceği sonucuna varılabilir.

Kaynakça

  • 1. https://www.cdc.gov/coronavirus/2019-ncov/index.html [Accessed date: 01.March. 2021].
  • 2. Turkish Republic Ministry of Health Covid-19 Guideline (https://covid19bilgi.saglik.gov.tr/depo/rehberler/COVID-19_Rehberi.pdf) [Accessed date: 01.March. 2021].
  • 3. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/[Accessed date: 01.March. 2021].
  • 4. Sun J, Deng X, Chen X, et al. Incidence of Adverse Drug Reactions in COVID-19 Patients in China: An Active Monitoring Study by Hospital Pharmacovigilance System. Clin Pharmacol Ther. 2020;108(4):791-7.
  • 5. Md Insiat Islam Rabby. Current Drugs with Potential for Treatment of Covid-19: A Literature Review. J Pharm Pharm Sci. 2020;23(1):58–64. 6. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054-62. 7. Şener A. COVİD-19 (SARS COV-2) Tedavisi. J Biotechinol & Strategic Health Res. 2020; 4: 97-104.
  • 8. Arapović J, Skočibušić S. The first two months of the COVID-19 pandemic in Bosnia and Herzegovina: Single-center experience. Bosn J Basic Med Sci. 2020;20(3):396-400.
  • 9. Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449-63. 10. Joshi S, Parkar J, Ansari Aet al. Role of favipiravir in the treatment of COVID-19. Int J Infect Dis. 2021;102:501-8.
  • 11. Ghasemnejad-Berenji M, Pashapour S. Favipiravir and COVID-19: A Simplified Summary. Drug Res (Stuttg). 2021;71(3):166-70.
  • 12. Sreekanth Reddy O, Lai WF. Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options. Chembiochem. 2021;22(6):939-48.
  • 13. Simonis A, Theobald SJ, Fätkenheuer G et al. A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2. EMBO Mol Med. 2021;13(1):e13105.
  • 14. İzci-Çetinkaya F, Karagöz H, Yıldız O. Comparison of liver safety of favipiravir and hydroxychloroquine in COVID-19 treatment. Klimik Derg 2020; 33(3): 235-40.
  • 15. Doğan E, Alkan-Çeviker S, Vurucu S, et al. [Investigation of the frequency of adverse effects in patients treated with favipiravir as SARS-CoV-2 treatment]. Klimik Derg. 2021; 34(2): 95-8.
  • 16. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-71.
  • 17. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16.
  • 18. Mutlu O, Uygun İ, Erden F. Koronavirüs Hastalığı (COVID-19) Tedavisinde Kullanılan İlaçlar. KOU Sag Bil Derg. 2020; 6(3): 167-73.
  • 19. Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A randomized clinical trial. JAMA Netw Open. 2020; 3(4): e208857
  • 20. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949. DOI: 10.1016/j.ijantimicag.2020.105949.
  • 21. Seyhan AU, Doganay F, Yilmaz E, et al. Investigation of QT Prolongation with Hydroxychloroquine and Azithromycin for the Treatment of COVID-19. J Coll Physicians Surg Pak. 2020;30(10):153-7.
  • 22. Gedikli MA, Tuzun B, Aktas, A et al. Are clarithromycin, azithromycin and their analogues effective in the treatment of COVID19? Bratisl Lek Listy. 2021;122(2):101-10.
  • 23. Réa-Neto Á, Bernardelli RS, Câmara BMD, et al. An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients. Sci Rep. 2021;11(1):9023. DOI: 10.1038/s41598-021-88509-9.
  • 24. Wang M, Liao Z. SARS-CoV-2 and COVID-19: How much do we know? Acta Virol. 2020;64(3):288-96.

Ayrıntılar

Birincil Dil İngilizce
Konular Sağlık Bilimleri ve Hizmetleri
Bölüm Orjinal Araştırma
Yazarlar

Sevil ALKAN (Sorumlu Yazar)
Çanakkale On sekiz Mart Üniversitesi Tıp Fakültesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Çanakkale
0000-0003-1944-2477
Türkiye


Taylan ÖNDER
ÇANAKKALE ONSEKİZ MART ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, ENFEKSİYON HASTALIKLARI VE KLİNİK MİKROBİYOLOJİ ANABİLİM DALI
0000-0003-0684-4047
Türkiye


Alper ŞENER
ÇANAKKALE ONSEKİZ MART ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, ENFEKSİYON HASTALIKLARI VE KLİNİK MİKROBİYOLOJİ ANABİLİM DALI
0000-0003-2774-8601
Türkiye


Ebru DOĞAN
ÇANAKKALE ONSEKİZ MART ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, ENFEKSİYON HASTALIKLARI VE KLİNİK MİKROBİYOLOJİ ANABİLİM DALI
0000-0001-6458-6408
Türkiye


Uğur GÖNLÜGÜR
Canakkale Onsekiz Mart University Faculty of Medicine,Chest Disease Department,Canakkale-Turkey
0000-0001-8720-2788
Türkiye


Tuncer ŞİMŞEK
Canakkale Onsekiz Mart University Faculty of Medicine Department of Anesthesiology and Reanimation
0000-0001-8035-7509
Türkiye


Adil Uğur ÇETİN
Canakkale Onsekiz Mart University Faculty of Medicine Department of Internal Medicine
0000-0002-2640-5386
Türkiye


Buse YÜKSEL
Usak Central Community Health Center,Turkey.
0000-0002-7959-618X
Türkiye

Destekleyen Kurum yok
Proje Numarası yok
Erken Görünüm Tarihi 1 Ocak 2022
Yayımlanma Tarihi 15 Mart 2022
Kabul Tarihi 20 Kasım 2021
Yayınlandığı Sayı Yıl 2022, Cilt 12, Sayı 2

Kaynak Göster

AMA Alkan S. , Önder T. , Şener A. , Doğan E. , Gönlügür U. , Şimşek T. , Çetin A. U. , Yüksel B. Comparisons of treatment protocols for SARS-COV-2 in early pandemic: Single center experience ın Turkey. J Contemp Med. 2022; 12(2): 182-188.